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Abstract 
The phosphoglucomutase (PGM)-encoding gene of Bordetella bronchiseptica is required for 
lipopolysaccharide (LPS) biosynthesis. An insertion mutant of the wild-type B. bronchiseptica strain 
BB7865 which disrupted LPS biosynthesis was created and characterized (BB7865pgm). Genetic analysis 
of the mutated gene showed it shares high identity with PGM genes of various bacterial species and 
forms part of an operon which also encompasses the gene encoding phosphoglucose isomerase. 
Functional assays for PGM revealed that enzyme activity is expressed in bothbvg-positive and 
bvg-negative strains ofB. bronchiseptica and is substantially reduced in BB7865pgm. Complementation 
of the mutated PGM gene with that from BB7865 restored the wild-type condition for all phenotypes 
tested. The ability of the mutant BB7865pgm to survive within J774.A1 cells was significantly reduced at 
2 h (40% reduction) and 24 h (56% reduction) postinfection. BB7865pgm was also significantly attenuated 
in its ability to survive in vivo following intranasal infection of mice, being effectively cleared from the 
lungs within 4 days, whereas the wild-type strain persisted at least 35 days. The activities of superoxide 
dismutase, urease, and acid phosphatase were unaffected in the PGM-deficient strain. In contrast, the 
inability to produce wild-type LPS resulted in a reduced bacterial resistance to oxidative stress and a 
higher susceptibility to the antimicrobial peptide cecropin P. 
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The phosphoglucomutase (PGM)-encoding gene of Bordetella bronchiseptica is required for lipopolysaccha-
ride (LPS) biosynthesis. An insertion mutant of the wild-type B. bronchiseptica strain BB7865 which disrupted
LPS biosynthesis was created and characterized (BB7865pgm). Genetic analysis of the mutated gene showed it
shares high identity with PGM genes of various bacterial species and forms part of an operon which also
encompasses the gene encoding phosphoglucose isomerase. Functional assays for PGM revealed that enzyme
activity is expressed in both bvg-positive and bvg-negative strains of B. bronchiseptica and is substantially re-
duced in BB7865pgm. Complementation of the mutated PGM gene with that from BB7865 restored the wild-
type condition for all phenotypes tested. The ability of the mutant BB7865pgm to survive within J774.A1 cells
was significantly reduced at 2 h (40% reduction) and 24 h (56% reduction) postinfection. BB7865pgm was also
significantly attenuated in its ability to survive in vivo following intranasal infection of mice, being effectively
cleared from the lungs within 4 days, whereas the wild-type strain persisted at least 35 days. The activities of
superoxide dismutase, urease, and acid phosphatase were unaffected in the PGM-deficient strain. In contrast,
the inability to produce wild-type LPS resulted in a reduced bacterial resistance to oxidative stress and a higher
susceptibility to the antimicrobial peptide cecropin P.
Of the Bordetella genus, Bordetella bronchiseptica is the prin-
ciple effector of respiratory disease in a wide range of mam-
mals (16). However, B. bronchiseptica only rarely infects hu-
mans (18, 46, 54). B. bronchiseptica is credited as being the
primary etiological component of tracheobronchitis in dogs
from as early as 1910 (14) and is known to be associated with
atrophic rhinitis, a common bronchial affliction of swine (40).
B. bronchiseptica infections are mediated by the controlled
expression of a number of virulence factors, such as the adhe-
sin filamentous hemagglutinin (10) and the toxins adenylate
cyclase hemolysin and dermonecrotic toxin (7, 50). The regu-
lation of these virulence determinants is under the control of a
two-component signal transduction system known as the Bor-
detella virulence gene (bvg) locus. Genetic control is observed
in response to environmental conditions such as temperature
and chemical modulators, i.e., sulfate anions (1, 27).
Lipopolysaccharide (LPS) is a highly toxic and immunogenic
molecule that constitutes a major component of the cell mem-
branes in gram-negative bacteria (37). LPS has now emerged
as having an integral role in the infection process, being re-
sponsible for resistance to serum, antibiotics (39), and natu-
rally occurring antimicrobial peptides termed defensins (5).
The role of LPS as an important adhesin molecule also seems
likely; however, its role in the pathogenesis process still re-
mains largely unknown. It has recently been stated that the
LPS of some strains of B. bronchiseptica is regulated by the bvg
system (48).
The LPS of the related bacterium Bordetella pertussis dis-
plays a structure that generally typifies that of nonenteric bac-
teria. This consists of a lipid A region anchored in the cell
membrane, being linked to a branched oligosaccharide domain
constituting the core, by a single keto-deoxyoctulosonic acid (2,
17, 48). These glycolipids lack long repeating oligosaccharide
units as are found in the Enterobacteriaceae and are therefore
sometimes termed lipooligosaccharides (37). B. bronchiseptica
and Bordetella parapertussis do, however, produce an O-anti-
gen of a single sugar polymer, consisting of 2,3-dideoxy-di-N-
acetylgalactosaminuronic acid (4, 13). There is considerable
variation in glycolipid structure within the genus Bordetella
(48).
Two distinct bands, i.e., band A and band B (35), are evident
upon electrophoresis of purified B. pertussis LPS. Band B con-
sists of the core region of the molecule, whereas the slower-
migrating band A is this same core with the addition of a distal
trisaccharide comprised of N-acetylglucosamine, N-acetyl-N-
methylfucosamine, and 2,3-di-deoxy-2,3-di-N-acetylmannos-
aminuronic acid (2). It is understood that all three elements of
the LPS molecule, i.e., lipid A, core, and O-antigen, are re-
quired for virulence of Escherichia coli (23). Viability of the
organism is not necessarily disrupted by the absence of the
O-antigen or several of the core sugars, but the keto-deoxyoc-
tulosonic residues of the core and the lipid A are essential for
growth (23). So important is the lipid A component of LPS to
the viability of the cell that it has been described as a suitable
pharmaceutical target (34).
A gene cluster for LPS production in B. pertussis and
B. bronchiseptica has been identified, and the probable func-
tions of the gene products have been discussed (2, 36); how-
ever, the role of LPS in the B. bronchiseptica infection process
remains largely undescribed. We describe here an LPS mutant
of B. bronchiseptica, designated BB7865pgm, resulting from an
insertion in the phosphoglucomutase (PGM)-encoding gene.
This gene appears to be organized into an operon with the
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phosphoglucose isomerase (PGI)-encoding gene. Regulation
of pgm is constitutive and is therefore controlled independently
of the bvg system. Loss of PGM activity due to insertional
mutation of the gene resulted in a truncation of the LPS. Re-
sistance to oxidative stress was reduced in the mutants as was
the ability to resist cecropin P. Finally, BB7865pgm was unable
to survive within the mouse macrophage-like cell line J774.A1
or colonize mouse lungs following intranasal inoculation.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. B. bronchiseptica wild-type
strain BB7865 and its isogenic bvg-negative derivative BB7866 have been
characterized in a previous study (33). E. coli strain SM10lpir (32) containing
pUTmini-Tn5 lacZ1 (11) was used in mutagenesis experiments. E. coli JM109
(55) was used in standard cloning experiments while E. coli 294 Rifr (51) was
used for cosmid cloning. B. bronchiseptica strains were grown on Bordet Gengou
(BG) agar (Difco) containing defibrinated horse blood (10%, vol/vol) and
Stainer and Scholte medium (SS-X) (45) or a modulating version of SS-X
containing 40 mM MgSO4 replacing NaCl (SS-C). Liquid cultures were also
grown in SS-X or SS-C. E. coli strains were grown on Z agar (51) or in LB broth
(41). The following antibiotics were used at the indicated concentrations: cepha-
lexin, 50 mg/ml; kanamycin, 50 mg/ml; ampicillin, 100 mg/ml; rifampin, 100 mg/ml;
nalidixic acid, 50 mg/ml; trimethoprim, 50 mg/ml. Isopropyl-b-D-galactopyrano-
side (IPTG) (0.04 mM) and 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside
(X-Gal) (0.004%, wt/vol) were used where appropriate.
Mini-transposon mutagenesis. Conjugation between B. bronchiseptica BB7866
and the donor E. coli SM10lpir containing the suicide plasmid (pUTmini-Tn5
lacZ1) was performed. Equal amounts of each bacterial strain were mixed in
0.7% saline and plated onto BG agar. Transconjugants were selected from the
resultant growth on SS-X at 37°C containing cephalexin, kanamycin, X-Gal, and
IPTG.
In vivo chromosome transfer. The method by which the mini-transposon was
transferred from BB7866pgm to the homologous location on the wild-type chro-
mosome (BB7865pgm) was that described by Smith and Walker (44). E. coli
Q358(pR715::Tn813) was mated with BB7866pgm. This resulted in the plasmid
being introduced into BB7866pgm. A permanent cointegration of the plasmid
into the chromosome occurred, catalyzed by the transposase encoded by Tn813.
This recombinant strain of BB7866pgm (Tpr Kmr) was then conjugally mated
with BB7865 (Nalr Rifr). Chromosome transfer is then promoted by the inte-
grated tra genes of pR751, and the recipient strain thus received the original Kmr
cassette following homologous recombination.
DNA manipulations. Plasmid DNA was extracted from host cells using midi-
prep columns in accordance with manufacturer’s instructions (Qiagen). Chro-
mosomal DNA was extracted according to the method of Priefer et al. (38).
Restriction endonuclease digestion and agarose gel electrophoresis were con-
ducted using standard methods (41). Cosmid cloning was achieved via the pack-
aging of recombinant cosmids (pHC79) (21) containing chromosomal DNA
fragments into lambda phage Max Plax kits (Epicentre Technologies) and sub-
sequent transduction into E. coli 294 Rifr cells. Desired clones were selected and
screened by colony hybridization. Chromosomal DNA for Southern hybridiza-
tion was transferred to positively charged nylon membranes by way of alkaline
transfer. Probe DNA was either digoxigenin labeled (Roche) or radiolabeled
with [a-32P]dATP using a nick translation kit (Gibco BRL). Blots were probed
under stringent conditions (65°C hybridization). Automated DNA sequencing
was performed on plasmid DNA with a Perkin Elmer ABI Prism 377 DNA
sequencer. Reactions were performed with Perkin Elmer BigDye terminator
cycle sequencing ready reaction mix. Contiguous sequences were constructed
using AutoAssembler software (Perkin-Elmer) and aligned with sequences in the
GenBank database located at the Australian National Genomic Information
Service by utilizing the Blastp algorithm.
PGM and phosphomannomutase (PMM) assays. Crude lysates were prepared
from the strains to be tested for mutase activity using the modified method from
Sandlin and Stein (42). Cultures of the strains were grown in either SS-X at 37°C
or SS-C at 25°C to late logarithmic phase and then centrifuged. The resultant
pellets were resuspended in 10 ml of sonication buffer (50 mM MOPS [morpho-
linepropanesulfonic acid], pH 7.0; dithiothreitol, 1 mM; EDTA, 3 mM). The cells
were again pelleted and resuspended in 1 ml of sonication buffer and frozen at
280°C. The cells were immediately thawed and sonicated five times at maximum
output for 15 s per burst (Branson Sonifier 250) and allowed to cool on ice
between bursts. The sonicated sample was centrifuged at 68,000 3 g for 20 min
to remove cellular debris. The resulting supernatant is the crude lysate used in
both mutase assays and was stored at 280°C until required. Protein concentra-
tion of the crude lysates were determined in triplicate with a standard Bradford
reagent assay (Sigma). PGM and PMM activities were determined essentially as
previously described (25, 42). Specific activities were expressed as milliunits per
milligram of protein, where 1 mmol of NADP (substrate) is reduced to NADPH
(product) in 1 min by 1 U of enzyme. NADPH production was calculated from
its molar extinction coefficient of 6,220. Lysates were tested in duplicate, and
three independent lysates were prepared.
LPS extraction. Cells were grown to late log phase in SS-C at 25°C or SS-X at
37°C to an A560 of 1.0 and concentrated to A560 1.5 in phosphate-buffered saline
(PBS). The resultant cell pellet from 500 ml of sample was resuspended in 100 ml
of distilled H2O. An equal volume of 23 sample buffer (6% sodium dodecyl
sulfate; 6% 2-mercaptoethanol; 10 mM dithiothreitol; 46% glycerol; 60 mM Tris,
pH 8.0; 0.1% bromophenol blue) was added, and the samples were boiled for 10
min. Protein was digested by the addition of proteinase K to a final concentration
of 50 mg/ml at 37°C overnight. Samples were again boiled for 10 min, and a
second volume of proteinase K, equal to the first, was added and incubated at
55°C for 3 h. LPS samples were stored at 220°C until required. LPS profiles were
determined by Tricine-sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis. Gels of 16.5% were assembled and electrophoresis was performed as de-
scribed by Lesse et al. (28). LPS was visualized by oxidative silver staining (47).
Complementation of pgm. The mini-transposon insertion into BB7865pgm
was complemented by the conjugal transfer into BB7865pgm of plasmid
pBBR1MCS-4 (26), which harbored a 1.5-kb SacII fragment containing the
complete pgm gene of BB7865. This plasmid was designated pBBR1MCS-4/
pgm1.
Resistance to oxidative stress. A disk diffusion assay was utilized to determine
sensitivity to paraquat (methyl viologen; Sigma) (22). Approximately 106 cells of
BB7865, BB7866, BB7865pgm, and BB7866pgm were plated onto SS-X or SS-C.
A filter with a pore size of 0.22 mm, presoaked in 10 mM paraquat, was placed
onto each plate, and this was followed by incubation at 30 or 37°C. Sensitivity to
paraquat was measured by the zone of inhibition surrounding the disk. The zone
was measured in two axes, and the mean values were calculated.
SOD, acid phosphatase, and urease assays. For superoxide dismutase (SOD)
assays, sonicated cell samples (100% output; four 15-s bursts) were cleared by
centrifugation (12,000 3 g for 2 min). A total of 115 mg of protein from each
sample was loaded onto an 8% native polyacrylamide gel and electrophoresed
according to standard procedures (52). Nitroblue tetrazolium was used to reveal
regions of enzyme activity as outlined by Beauchamp and Fridovich (6). Acid
phosphatase and urease activities were determined as previously described (22,
24, 31).
Cecropin P radial diffusion and liquid killing assays. The sensitivity of the
mutant strains to cecropin P, a bioreactive peptide, was tested. Radial diffusion
assays were performed essentially as described previously (5). Bacteria were
cultured on BG agar before being resuspended to a final optical density of 0.2 at
A600 in SS-C or SS-X. Low-gelling-temperature agarose (1%) in either SS-X or
SS-C was prepared and when cool was supplemented with bovine serum albumin
(final concentration, 0.15%). To 10-ml aliquots, 200-ml aliquots of the cell sus-
pensions were added and allowed to set in a standard 90-mm-diameter petri dish.
Cecropin P (5 mg; 1 mg/ml in H2O; Sigma) was added to 3-mm-diameter wells
made in the agarose. Following incubation at room temperature for 4 h, the
plates were transferred to 37°C (SS-X plates) until zones were clearly visible. For
liquid killing assays, BB7865 and BB7865pgm were cultured on SS-X at 37°C and
suspended in PBS. Equal volumes of the cell suspension and cecropin P were
combined, giving a final peptide concentration of 50 mg/ml. Following 1.5 h of
incubation at 37°C, serial dilutions were performed on BB7865 and BB7865pgm,
with and without cecropin P; plated onto SS-X; and incubated at 37°C.
Tissue culture. The mouse macrophage-like cell line J774.A1 (ATCC TIB 67)
was maintained in Dulbecco’s modified Eagle medium supplemented with 10%
fetal calf serum (vol/vol) and 5 mM glutamine in an atmosphere containing CO2
(5%, vol/vol) at 37°C. Approximately 5 3 104 cells were seeded per well in
24-well tissue culture plates, incubated for 18 h, and then washed twice with
complete medium. For invasion assays the method essentially followed that
described by Guzmán et al. (19). The results reported are mean values of three
independent assays with standard deviations. Incubation of B. bronchiseptica
bacteria, resuspended to an optical density equal to that used in the invasion
assays in Dulbecco’s modified Eagle medium supplemented with gentamicin at
50 mg/ml for 2 h resulted in .6 orders of magnitude of reduction in CFU.
Murine respiratory infection model. Female BALB/c mice at 6 to 10 weeks of
age were used as a model of in vivo respiratory infection by B. bronchiseptica.
Following treatment with Ketamine (50 mg/kg) and Xylazine (10 mg/kg) in
sterile PBS, two 12.5-ml aliquots of a bacterial suspension were delivered intra-
nasally to each mouse via an air-displacement pipette and the mouse was allowed
to recover. The total number of viable bacteria administered was approximately
105 cells. At each time point four mice from each group were sacrificed and their
lungs were removed aseptically. Lungs were homogenized in sterile physiological
saline, and appropriate dilutions were plated onto nutrient agar to determine the
number of viable bacteria present in the lungs.
Statistics. The results tested for statistical significance were subjected to Stu-
dent’s t test. Differences were considered significant if P was #0.05.
Nucleotide sequence accession number. The nucleotide sequence data for
PGM and PGI have been submitted to the GenBank database under the acces-
sion number AF171632.
RESULTS
Identification of a novel LPS genetic locus in B. bronchisep-
tica. A mini-Tn5 mutant of the BvgS mutant strain BB7866 was
produced (designated BB7866pgm) that demonstrated an in-
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ability to synthesize a complete LPS molecule, as demon-
strated by oxidative silver staining of LPS extracts. Initial DNA
sequence data obtained from a cosmid clone positive for the
mini-Tn5 in Southern blots (data not shown) allowed the pro-
duction of PCR primers adjacent to the insertion site. These
primers enabled the amplification of a 300-bp gene fragment
which was utilized to probe a BB7865 cosmid library. The
result of these investigations, following cosmid cloning and
subcloning, was a 3.4-kb NotI fragment shown to contain a
complete gene (Fig. 1A) with an amino acid sequence identity
of 55% (72% similarity) with the PGM gene from Neisseria
gonorrhoeae (Fig. 1B). The PGM gene was shown via Southern
FIG. 1. Genetic organization and sequence homology of pgm. (A) Spatial orientation of the operon from B. bronchiseptica containing pgm and pgi. The equivalent
genes were found to exist in B. pertussis in the same orientation and with high DNA sequence homology (98.6 and 99.3%, respectively). A gene downstream of
B. pertussis pgi was located and shown to have the highest homology with other galactosyl transferases. The dashed line indicates the fragment of DNA cloned into
pBBR1MCS-4 (26) and thereafter utilized for complementation of BB7865pgm. Arrows indicate the direction of transcription. Arrowheads indicate putative promoter
sequences. (B) ClustalW alignment of B. bronchiseptica (Bbro) pgm gene and the following homologous sequences (pgm and pmm) (abbreviations and accession
numbers are given in parentheses): Neisseria meningitidis pgm (Nmen; P40391), N. gonorrhoeae pgm (Ngon; P40390), P. aeruginosa pmm (Paer; P26276), Azospirillum
brasilense pmm (Abra; P45632), and Prochlorothrix hollondica pmm (Phol; U23551). Identical residues are depicted by dots. Dashes indicate gaps introduced in the
amino acid sequence for optimal alignment.
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blotting to hybridize with DNA fragments of B. pertussis and
B. parapertussis but not with Bordetella avium (Fig. 2). Sepa-
rated by just 10 bp and downstream of the PGM-encoding
gene, a second open reading frame was identified which exhib-
its high homology with the PGI gene from several organisms.
These two genes appear to be organized into an operon (Fig.
1A) based on their spatial organization and the absence of an
intervening promoter-like sequence. PGI is also found in a
similar genetic organization in B. pertussis and shares 99.3%
nucleotide sequence homology with the B. bronchiseptica pgi
gene as sequenced thus far (the B. pertussis genome is found on
line at http://www.sanger.ac.uk/Projects/B_pertussis/). This op-
eron has not been previously described in Bordetella. An open
reading frame located downstream of the pgi gene from B. per-
tussis has been identified as encoding a possible galactosyl
transferase; however, this gene is not included within the pgm
operon. The identical gene was mutated in BB7865, the pa-
rental strain of BB7866, by way of an in vivo chromosome
transfer technique (44). This allowed for the effects of such a
mutation to be observed in a bvg-positive background. The
resultant mutant was designated BB7865pgm.
Analysis of PGM enzyme activity from BB7865, BB7866, and
their respective pgm-deficient mutants. PGM assays were per-
formed to determine the level of enzyme activity in parental
and mutant strains. These assays demonstrate that the muta-
tion eliminates the ability to produce functional enzyme, as
BB7865pgm and BB7866pgm are shown to have a PGM activity
below the detection limits of the assay (i.e., ,2 mU/mg). This
was shown to be statistically significant (P #0.01) for strains
grown in either SS-C at 25°C or SS-X at 37°C (Table 1). PMM
assays were also performed, as the mutated gene also shared
high amino acid homology to PMM from Pseudomonas aerugi-
FIG. 2. Characterization of the pgm insertion mutation. (A) The mini-Tn5 insertion (5.0 kb) was found to have occurred 604 bp downstream of the pgm methionine
start codon. (B) Southern blot analysis of pgm mutants and other Bordetella spp. utilizing the 300-bp PCR fragment (PCR-1), amplified adjacent to the mini-transposon
insertion (see panel A). The pgm gene exists in an EcoRI fragment of 8.4 kb. An EcoRI site located on the transposon results in a restriction fragment 539 bp shorter
than that of the wild type. Lane 1, BB7865; lane 2, BB7866; lane 3, BB7865pgm; lane 4, BB7866pgm; lane 5, B. pertussis; lane 6, B. parapertussis; lane 7, B. avium.
TABLE 1. Specific activities of PGM and PMM in
B. bronchiseptica wild-type and mutant strainsa
Strain
Sp act (mU/mg) of enzyme under condition:
PGM PMM
SS-C, 25°C SS-X, 37°C SS-C, 25°C SS-X, 37°C
BB7866 7.37 6 0.39 6.3 6 0.32 10.9 6 1.1 6.36 6 0.3
BB7866pgm 1.9 6 0.45 0.29 6 0.13 1.75 6 0.33 1.14 6 0.06
BB7865 7.17 6 0.23 6.26 6 0.28 8.12 6 0.77 6.4 6 0.4
BB7865pgm 0.46 6 0.3 0.81 6 0.23 1.31 6 0.55 0.9 6 0.36
BB7865pgm
(pBBR1MCS-4/pgm1)
9.1 6 0.83 7.75 6 1.7 11.1 6 0.42 7.2 6 1.12
a Assays were conducted in triplicate for cells grown under modulating and
nonmodulating conditions. Assays were performed with independent lysates on
three occasions. Values shown are means 6 standard errors of the means.
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nosa. Similar results were obtained for this enzyme, with PGM
mutants again displaying low levels of activity, whereas the wild
type expressed levels closer to 8.12 mU/mg. Complementation
of BB7865pgm with the wild-type pgm gene restored PGM and
PMM activity to levels observed in BB7865. It is of interest that
PGM is known to be a bifunctional enzyme (42) capable of
using either glucose or mannose as a substrate. Mannose, how-
ever, is not reported as a component of the B. pertussis LPS (3);
it therefore seems likely that the affected enzyme acts as PGM
in B. bronchiseptica.
Electrophoretic profiles of LPS extractions clearly demon-
strate the physical alterations caused by the mutation of PGM
(Fig. 3A). The band A and band B core structures (35) and the
O-antigen are all seen to be present in the parental strains (Fig.
3A). However, O-antigen is absent from BB7865pgm and
BB7866pgm, and the core structure is considerably truncated,
migrating faster than the band B of the parental strains.
Complementation with pgm from the parental BB7865 strain
restored the wild-type LPS phenotype to BB7865pgm (Fig.
3A). The influence of the bvg locus on the expression of PGM
was analyzed. At 37°C and in the absence of chemical modu-
lators such as MgSO4, virulence factors are expressed. There
exists a separate class of genes that are repressed by the bvg
locus, including the genes encoding flagellum biosynthesis (1).
This occurs with growth in modulating medium, i.e., contain-
ing MgSO4, at lower temperatures (25°C). The size of the LPS
molecule from the mutant strains is unaffected by growth un-
der either modulating or nonmodulating conditions, as is the
case for the wild type, indicating that the bvg locus elicits
control only over the distal region of the molecule including
the O-antigen. PGM and PGI are both required early in the
pathway for production of sugar nucleotides destined for LPS
FIG. 3. LPS phenotypes and biosynthesis pathway. (A) Electrophoretic profiles of LPS extracted from BB7865 (lanes 1 and 5), BB7866 (lanes 2 and 6), BB7865pgm
(lanes 3 and 7), and BB7866pgm (lanes 4 and 8); lanes 9 and 10 contain the complemented mutant, BB7865pgm (pBBR1MCS-4/pgm1). Strains represented in lanes
1 to 4 and 9 were cultured in SS-C at 25°C, whereas those shown in lanes 5 to 8 and 10 were cultured in SS-X at 37°C. O-antigen and core band A and B are indicated
to the left. (B) Biosynthesis of nucleotide sugars via pgm and pgi for production of LPS. (Modified from reference 56 with permission of the publisher.)
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synthesis. In fact they both catalyze the same substrate, glucose
1-phosphate, converting it to the respective precursors (Fig.
3B).
Intracellular survival of parental and PGM-deficient B. bron-
chiseptica. In vitro invasion and survival assays utilizing J774.A1
cells demonstrated a significantly reduced ability of the mutant
strains to survive. Compared to the CFU of the respective pa-
rental strains, only 43% of BB7865pgm and 40% of BB7866pgm
remained after 24 h (Fig. 4). Complementation of BB7865pgm
with the wild-type pgm gene restored survival rates to levels
above those observed in BB7865.
Highly reactive oxygen anion radicals are an effective intra-
cellular defense mechanism employed by the host. Intracellu-
lar bacteria can utilize various enzymes such as SOD for the
conversion of these radicals to more stable forms, i.e., O2
2 to
H2O2 and O2. Of interest here is the effect of a compromised
physical barrier to free radical attack; therefore, sensitivity of
PGM mutants to oxidative stress was measured. BB7865pgm
was notably more sensitive to paraquat (Table 2), a superoxide
radical-generating compound, exhibiting a zone of inhibition
of 8.5 mm on SS-C at 25°C and 7 mm on SS-X at 37°C com-
pared to 0 mm for BB7865 under both conditions. Comple-
mentation of BB7865pgm with the wild-type pgm gene restored
the wild-type phenotype. SOD activity levels remained un-
changed for BB7865pgm (results not shown), suggesting a role
for LPS as a physical barrier. Other phenotypes tested that are
suggested to participate in intracellular survival within eu-
karyote cells are acid phosphatase (9) and urease (31). These
phenotypes remained unaffected in the BB7865pgm mutant
(results not shown).
Resistance to the cationic peptide cecropin P. LPS is cred-
ited as being responsible for conferring some protection against
antibiotics and serum (53) as a mode of protection from host
defenses. Another naturally occurring class of molecules are
the defensins. These are cationic peptides found in a wide va-
riety of vertebrate and invertebrate organisms (15) on the sur-
face of skin, trachea, and tongue among others (20, 43). The
sensitivity of BB7865pgm to the defensin cecropin P in a radial
diffusion assay was shown to be significantly increased (P # 0.01)
compared to that of the wild-type strain (Table 3). Comple-
mentation of BB7865pgm with the wild-type pgm gene restored
the wild-type phenotype in radial diffusion assays. It was also
established that 90% of BB7865pgm, compared to BB7865
cells, were killed when incubated with a 50-mg/ml solution of
cecropin P for 1.5 h in liquid killing assays (results not shown).
Survival of BB7865pgm within the murine respiratory tract.
In vitro survival assays demonstrated a marked reduction in the
ability of the PGM mutant to invade or persist within J774.A1
cells (Fig. 4). This result led to the investigation of the effect
the B. bronchiseptica pgm mutation would have within a murine
respiratory infection model. Nonlethal doses of BB7865 or
BB7865pgm were administered to BALB/c mice intranasally,
and the numbers of CFU present in the lungs were measured
at various time points following infection. Although the wild-
type strain showed a classic pattern of infection (22), the
mutant strain was unable to survive, being effectively cleared
within 4 days. This was the result observed in two independent
trials. The reduction in BB7865pgm CFU was found to be
consistently significant from day 2 (P # 0.05). Mice infected
with the wild-type strain still had an average of 1,000 CFU/lung
persisting 35 days following inoculation (Fig. 5).
FIG. 4. Intracellular survival of B. bronchiseptica strains in J774.A1 cells at 2
and 24 h. Results shown are represented as mean percentages of CFU recovered
of the respective parental strains. Error bars indicate the standard error of the
mean.
TABLE 2. Sensitivity of B. bronchiseptica to oxidative stress as
measured by disk diffusion of paraquata
Strain
Zone of inhibition (mm) under condition:
30°C 37°C
SS-C SS-X SS-C SS-X
BB7866 0 6 0 0 6 0 0 6 0 0 6 0
BB7866pgm 4.5 6 0.5 3.5 6 0.5 3.5 6 0.5 1.5 6 1.5
BB7865 0 6 0 0 6 0 0 6 0 0 6 0
BB7865pgm 8.5 6 1.5 3 6 3 10.5 6 0.5 7 6 0
BB7865pgm
(pBBR1MCS-4/pgm1)
0 6 0 0 6 0 0 6 0 0 6 0
a Values shown are means for three separate assays 6 standard errors of the
means.
TABLE 3. Sensitivity of B. bronchiseptica wild-type and mutant
strains to cecropin P as measured by radial diffusion
Strain Inhibitionzonea (mm)
BB7866 ........................................................................................... 11
BB7866pgm .................................................................................... 17
BB7865 ........................................................................................... 11.3
BB7865pgm .................................................................................... 16.3
BB7865pgm (pBBR1MCS-4/pgm1)............................................. 10.6
a Inhibition zone refers to the diameter of the region of growth inhibition.
FIG. 5. In vivo persistence of wild-type BB7865 and the pgm mutant,
BB7865pgm, in a murine respiratory model. Lungs were taken at different time
intervals, and the number of viable bacteria per lung was determined. The results
are averages of values for four mice.
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DISCUSSION
A new gene cluster critically involved in the production of
LPS in B. bronchiseptica is described here. The operon includes
genes identified as encoding PGM and PGI, which are utilized
in the synthesis of nucleotide sugars for inclusion into growing
LPS molecules. Abolition of PGM activity will lead to the loss
of glucose and all other components distal to the heptose
residue of the B. bronchiseptica inner core (i.e., band A, band
B, and O-antigen). Of further interest is the fact that the
abolition of PGM activity renders the bacteria more suscepti-
ble to antimicrobial peptides and oxidative stress, reduces bac-
terial ability to survive within J774.A1 cells, and results in an
inability to colonize the murine respiratory tract. Complemen-
tation of the PGM mutant B. bronchiseptica pgm with the
wild-type pgm gene restored the wild-type condition for all
phenotypes tested, indicating that the mutation of pgm was
responsible for the altered phenotypes observed in this study.
The role played by the bvg locus in regard to the regulation
of the PGM operon was investigated and was not found to be
required for expression. The bvg locus has been shown in this
study and in others (48) to influence the expression of LPS in
response to a modulating environment (i.e., reduced temper-
ature and increased sulfate anions). This is exemplified by the
identical LPS profile of the bvg-negative mutant BB7866 and
BB7865 grown in SS-C at 25°C compared to the contrasting
LPS profile seen in BB7865 when grown in SS-X at 37°C. It has
been observed that LPS expressed by B. bronchiseptica can
change during an infection (17). This type of expression has
been suggested to be a mechanism of adaptation to the host
environment in other mucosal pathogens such as P. aeruginosa
and N. gonorrhoeae (12, 49). The length of the O-antigen has
been demonstrated to be an important factor for resistance to
complement (8). It is therefore feasible that regulation of the
LPS composition includes one form required for colonization
or invasion and another for survival in a particular niche pro-
tected from host humoral defenses. The bvg-repressed form of
LPS may also be advantageous to the cell during transmission
between hosts. Other evidence existing for bvg-regulated LPS
expression includes monoclonal antibodies specific for band B
LPS of B. pertussis, which only react with B. bronchiseptica LPS
in a bvg-repressed state (30).
However, pgm is not regulated by bvg. There is not a signif-
icant difference in the activity of the enzyme produced by
bvg-positive or bvg-negative parental strains under any growth
condition. This result is mirrored in the LPS profiles of the
mutant strains that indicate the same size LPS molecule is
produced for both, irrespective of growth conditions. A possi-
ble explanation for this observation is that the early core bio-
synthesis is not bvg-regulated. These genes are likely to be
expressed as housekeeping genes rather than being controlled
by the virulence regulator. Genes utilized for the synthesis of
the LPS molecule distal to the core glucose are not required
for growth but are utilized for virulence and thus may be
regulated by the bvg locus. This hypothesis also seems likely
given that the genes of the PGM operon are distinct from the
other LPS biosynthesis genes, such as the wlb genetic locus
responsible for band A biosynthesis and also involved in O-
antigen production. Strengthening this point is the existence of
the waaA and waaC genes (required for synthesis of the deep
inner core), which are not incorporated in the wlb locus (3, 36).
The importance of LPS to pathogenesis can be inferred by
the B. bronchiseptica pgm mutant. The results obtained from
the murine respiratory infection model demonstrate that al-
though lipid A and the deep inner core are sufficient for via-
bility, this truncated form of LPS is inadequate for colonization
and survival of B. bronchiseptica in vivo. The absence of the
O-antigen is likely to be a major factor in the behavior of
BB7865pgm mutant in vivo. The increased sensitivity to de-
fensins is probably due to the lack of the O-antigen and may
offer some reason as to why bacterial clearance was so efficient.
The antimicrobial peptide tested in this study was of the
cecropin class. These, like the defensins, are cationic peptides
and play an important role in the innate immunity of the host
respiratory tract. The mode of action of the peptides is the
destabilization of the cellular membrane by binding with an-
ionic phospholipids (29). The O-antigen of B. bronchiseptica is
thought to constitute a protective barrier, thereby concealing
the negative charge of the membrane (5).
Resistance to superoxide anions is an important factor in
terms of bacterial intracellular survival. Evidence to suggest
that LPS is in some way responsible for a level of protection
from intracellular superoxide radicals may come from the fact
that the mutants were more susceptible to paraquat despite
SOD levels remaining at wild-type levels (results not shown).
Again, the high charge of B. bronchiseptica O-antigen may be
able to shield the cell from the destructive O2
2 radicals, at
least at the concentration tested in this study.
The bvg regulation of the distal portion of the LPS molecule
is in response to the environment in which the bacterium finds
itself. The pathogen must be capable of expressing an O-anti-
gen of the correct length and composition. Sequential mu-
tagenesis of the LPS molecule from the distal region would be
required to highlight which portion of the molecule is specif-
ically required for pathogenesis.
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